Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967005 · ClinicalTrials.gov registry record · Phase 2
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
A Phase 2 study of Tobacco Use Disorder and Gambling, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00967005: Completed Phase 2 study of Tobacco Use Disorder and Gambling, sponsored by University of Chicago.
NCT00967005 is a Phase 2 study of Tobacco Use Disorder and Gambling that has completed, run by University of Chicago. The registered enrollment target is 28 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00967005, a Phase 2 study of Tobacco Use Disorder and Gambling, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
Primary Outcome
Week 0 corresponds to baseline. Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.
Conditions Studied
Interventions
- DRUG N Acetyl Cysteine
- OTHER Sugar Pill
Study Locations (2)
Connecticut
- Yale University School of Medicine - New Haven
Minnesota
- University of Minnesota School of Medicine - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT00967005 record still lists
NCT00967005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which N Acetyl Cysteine is the first listed.
NCT00967005 reports a single indexed study location in Connecticut, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00967005 about?
NCT00967005 is a clinical study titled "N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers". The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
What is the current status of trial NCT00967005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-09. Estimated completion is 2014-08.
What conditions does trial NCT00967005 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Gambling.
What interventions are being tested in trial NCT00967005?
The interventions under investigation include: N Acetyl Cysteine (DRUG), Sugar Pill (OTHER).
Who is sponsoring clinical trial NCT00967005?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00967005 being conducted?
This trial has 2 study locations across Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00967005's enrollment target sits among peer trials
28 63rd of 70 higher than 8 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia